Testicular Cancer Diagnosis and Tests

Urology: Urinary & Reproductive Disease Diagnosis & Treatment

Urology treats urinary tract diseases in all genders and male reproductive issues, covering the kidneys, bladder, prostate, urethra, from infections to complex cancers.

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

Advanced Ultrasonography and Imaging

The diagnostic algorithm for testicular cancer begins with high-frequency scrotal ultrasonography. This non-invasive modality uses sound waves to create detailed images of the testicular parenchyma. A solid, hypoechoic (darker) mass within the testicle is the classic sonographic appearance of a tumor. Modern ultrasound devices use elastography to measure tissue stiffness. Malignant tumors are typically more complex and stiffer than healthy tissue or benign cysts. This added functional parameter improves the specificity of the diagnosis.

Contrast-enhanced ultrasound is another technological advancement. By injecting microbubble contrast agents, clinicians can visualize the lesion’s vascularity. Malignant tumors typically exhibit greater vascularity than the surrounding tissue. This helps distinguish avascular lesions, such as hematomas or infarcts, from active neoplasms. For staging, Computed Tomography (CT) of the abdomen and pelvis is mandatory to evaluate the retroperitoneal lymph nodes. A chest CT is performed to rule out pulmonary metastases. In complex cases or when avoiding radiation is a priority (e.g., surveillance), Magnetic Resonance Imaging (MRI) offers superior soft-tissue contrast and is increasingly used for follow-up.

Serum Tumor Markers

Biochemical diagnosis relies on specific serum tumor markers: Alpha-Fetoprotein (AFP), the beta subunit of Human Chorionic Gonadotropin (β-hCG), and Lactate Dehydrogenase (LDH). These markers are proteins secreted by the tumor cells into the bloodstream. AFP is produced by non-seminomatous tumors, specifically yolk sac elements. B-hCG can be elevated in both seminomas and non-seminomas. LDH is a non-specific marker of tissue turnover but correlates with tumor burden and bulky disease.

The levels of these markers are critical for diagnosis, staging, and risk stratification. They also serve as the primary tool for monitoring treatment response. A rapid decline in marker levels following orchiectomy or chemotherapy indicates effective treatment, while a plateau or rise suggests residual or resistant disease. The rate of decrease is determined by the marker’s half-life, a pharmacokinetic parameter that guides clinical decision-making.

MicroRNA: The New Frontier

A revolutionary development in testicular cancer diagnosis is the identification of microRNAs, specifically miR-371a-3p. These are small, non-coding RNA molecules released by malignant germ cells. Clinical studies have demonstrated that miR-371a-3p is significantly more sensitive and specific than the traditional protein markers (AFP, hCG, LDH) for detecting active germ cell tumors.

This biomarker has the potential to detect microscopic disease that is invisible on CT scans and to differentiate between viable cancer and benign scar tissue (teratoma) after chemotherapy. The integration of miR-371a-3p testing into clinical practice represents a shift towards molecular precision, potentially reducing the need for repeated radiation exposure from CT scans and sparing patients from unnecessary surgeries.

Liquid Biopsy and Circulating Tumor Cells

Liquid biopsy technology involves analyzing blood samples for Circulating Tumor Cells (CTCs) or Circulating Tumor DNA (ctDNA). This approach offers a real-time snapshot of the tumor’s genetic landscape. By sequencing the DNA from these circulating cells, clinicians can identify specific mutations that may drive resistance to chemotherapy.

This technology is particularly valuable in the setting of metastatic disease. It allows monitoring of clonal evolution, in which the tumor changes its biological behavior under treatment pressure. Detecting these changes early allows adaptation of therapeutic strategies before clinical relapse.

Histopathological and Molecular Characterization

The definitive diagnosis is obtained through radical inguinal orchiectomy, where the testicle is removed and examined by a pathologist. Immunohistochemistry uses antibodies to detect specific cell-surface proteins, such as PLAP, OCT4, and CD30, to categorize tumor type precisely.

Molecular pathology is expanding to include analysis of the tumor’s genetic instability and mutation burden. Understanding specific chromosomal aberrations, such as the isochromosome 12p, helps confirm the germ cell origin and predict biological aggressiveness.

Biochemical Markers and Signaling Pathways

miR-371a-3p expression levels (superior sensitivity).
Alpha fetoprotein half-life kinetics (5 to 7 days).
Beta hCG half-life kinetics (24 to 36 hours).
Lactate Dehydrogenase isoenzyme analysis.
Placental Alkaline Phosphatase (PLAP) staining.

Physiological Stages of Condition

Localized disease confined to the testis (Stage I).
Regional metastasis to retroperitoneal nodes (Stage II).
Distant metastasis above the diaphragm (Stage III).
Marker-negative disease with radiological findings.
Platinum refractory progression.

Advanced Technological Requirements

High-frequency ultrasound with elastography.
Quantitative PCR for microRNA detection.
Next Generation Sequencing for liquid biopsy.
Diffusion weighted MRI for lymph node assessment.
Automated immunoassays for tumor markers.

Systemic Risk Factors and Metabolic Comorbidities

Renal function assessment for contrast clearance.
Liver function impact on AFP metabolism.
Hypogonadism affects baseline blood parameters.
Marijuana use confounds marker interpretation.
False positive hCG from hypogonadotropic states.

Comparative Clinical Objectives

Accurate histological subtyping (Seminoma vs. Non-Seminoma).
Precise staging to determine chemotherapy need.
Identification of occult metastatic disease.
Establishment of baseline marker nadir.
Differentiation of viable tumor from teratoma or necrosis.

Book a Free Certified Online
Doctor Consultation

Related Doctors

Liv Hospital Ulus Prof. MD. Engin Kaya Urology

Liv Hospital Ulus Prof. MD. Orhan Tanrıverdi Urology

Liv Hospital Ulus Prof. MD. Tahir Karadeniz Urology

Liv Hospital Ulus Prof. MD. Uğur Boylu Urology

Liv Hospital Vadistanbul Assoc. Prof. MD. Eymen Gazel Urology

Liv Hospital Vadistanbul Op. MD. Kenan Yiğit Yıldız Urology

Liv Hospital Vadistanbul Op. MD. Miraç Turan Urology

Liv Hospital Vadistanbul Prof. MD. Selçuk Şahin Urology

Liv Hospital Vadistanbul Prof. MD. Volkan Tuğcu Urology

Liv Hospital Vadistanbul Prof. MD. Yusuf Oğuz Acar Urology

Liv Hospital Vadistanbul Spec. MD. Anar Mammadov Urology

Liv Hospital Bahçeşehir Op. MD. Fırat Akdeniz Urology

Liv Hospital Bahçeşehir Prof. MD. Ayhan Karaköse Urology

Liv Hospital Topkapı Op. MD. Birgi Ercili Urology

Liv Hospital Topkapı Prof. MD. Kadir Önem Urology

Liv Hospital Topkapı Spec. MD. Timuçin Çakır Urology

Liv Hospital Ankara Asst. Prof. MD. Ahmet Yıldız Urology

Liv Hospital Ankara Prof. MD. Ziya Akbulut Urology

Liv Hospital Ankara Prof. MD. Çağrı Güneri Urology

Liv Hospital Gaziantep Op. MD. Kazım Doğan Urology

Liv Hospital Gaziantep Prof. MD. Faruk Küçükdurmaz Urology

Liv Hospital Samsun Op. MD. Çağlar Yıldırım Urology

Liv Hospital Samsun Op. Md. İdris Kıvanç Cavıldak Urology

30 Years of Excellence

Trusted Worldwide

With patients from across the globe, we bring over three decades of medical

Reviews from 9,651

4,9

Worth a look

Was this article helpful?

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

FREQUENTLY ASKED QUESTIONS

Why can’t the tumor be biopsied through the scrotum?

Biopsying a testicular tumor through the scrotum is contraindicated because it can disrupt the lymphatic drainage of the testicle. The testicle drains to the abdomen, but the scrotum drains to the groin. Cutting into the scrotum could spill cancer cells into a new lymphatic pathway (the inguinal nodes), spreading the cancer to an area where it usually wouldn’t go and complicating treatment.

What if my tumor markers are regular?

Having regular tumor markers does not mean you don’t have cancer. Some testicular cancers, exceptionally pure seminomas and teratomas, do not secrete AFP or hCG. These are called “marker negative” tumors. In these cases, the diagnosis relies on the ultrasound appearance and the pathology report after the testicle is removed.

What is a “burned-out” tumor?

Sometimes, the body’s immune system attacks the primary testicular tumor, causing it to regress and leaving only a small scar. However, before it was destroyed, the cancer may have spread to the lymph nodes. A “burned out” tumor presents as metastatic cancer in the abdomen with no apparent mass in the testicle, only a scar visible on ultrasound.

Is a CT scan safe for young men?

CT scans use ionizing radiation. While a single scan is low risk, young men with testicular cancer often need many scans over the years of surveillance. Cumulative radiation can slightly increase the risk of secondary cancers later in life. Therefore, doctors try to use MRI (which emits no radiation) or minimize the number of CT scans whenever it is safe to do so.

What does the miR-371 test do?

The miR-371 test detects specific microRNAs in blood released by testicular cancer cells. It is a new, highly accurate test that works even for many patients who have normal AFP and hCG levels. It is expected to become a significant tool for detecting relapse earlier and avoiding unnecessary treatment in the near future.